

1-1-1998

Distribution of Tamoxifen in Rat Tissues During Steady-State Treatment

Ayşe KAFKASLI

Erkan ÜNLENEN

Beyhan DEMİRHAN

Saim YOLOĞLU

Follow this and additional works at: <https://journals.tubitak.gov.tr/medical>



Part of the [Medical Sciences Commons](#)

Recommended Citation

KAFKASLI, Ayşe; ÜNLENEN, Erkan; DEMİRHAN, Beyhan; and YOLOĞLU, Saim (1998) "Distribution of Tamoxifen in Rat Tissues During Steady-State Treatment," *Turkish Journal of Medical Sciences*: Vol. 28: No. 6, Article 2. Available at: <https://journals.tubitak.gov.tr/medical/vol28/iss6/2>

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.

Ayşe KAFKASLI¹
Erkan ÜNLENEN²
Beyhan DEMİRHAN³
Saim YOLOĞLU⁴

Distribution of Tamoxifen in Rat Tissues During Steady-State Treatment

Received: April 08, 1996

Department of ¹Obstetrics and Gynecology,
Faculty of Medicine, İnönü University,

⁴Biostatistics, Malatya-Turkey

²Department of Nuclear Medicine,

Gazi University, Ankara-Turkey

³Department of Pathology, Faculty of Medicine,
Başkent University, Ankara-Turkey

Abstract: Tamoxifen citrate (TAM), a nonsteroidal antiestrogen, is a drug of choice in the endocrine treatment for all stages of breast cancer in both pre and postmenopausal patients. The tissue distribution of TAM alone and combined with medroxyprogesterone acetate (MPA)

following long-term p.o. administration in immature rats is investigated in the present study. The highest concentrations of TAM has been found in the hypophysis in both groups. TAM concentrations were effected by MPA treatment in the liver and kidneys.

Introduction

Tamoxifen citrate is a first-line endocrine treatment for estrogen receptor positive breast cancer patients (1). TAM has also been considered as a chemopreventive agent, for the primary prevention of breast cancer in high risk women (2). Although the mode of action is not clear yet, TAM acts as an estrogen antagonist in the presence of high endogenous estrogen levels and it may also act as a weak estrogen agonist when the endogenous estrogen levels are low (3). TAM is metabolized in the liver and several metabolites have been detected in serum (4). In serum, 98% of the tamoxifen is bound to albumin and the distribution volume of the drug is high (50-60 liters/kg) (5). The high volume distribution of TAM suggests the extensive distribution of the drug into the peripheral tissues and the presence of a small amount in serum. Tissue distribution of the TAM and its metabolites have been reported both in rats and human following p.o or i.v. administrations (6-9). Since the tumorostatic effect of TAM is directly related to its concentration in tumor cells in rats, the tissue distribution of TAM is important (10).

Since MPA is known to prevent estrogen induced changes in endometrium, MPA is commonly administered together with TAM (11).

The present study was designed to evaluate the tissue distribution of TAM in immature rats following long-term p.o. administration.

Materials and Methods

Animals

Sixteen immature (21 days) Female Wistar rats were purchased from Medical Research Institute of Istanbul University and divided into 2 groups randomly. All animals were maintained on a 12h light- 12h dark cycle. Water and pelleted food were supplied ad libitum.

Drugs

TAM (ICI Pharmaceuticals, Wilmington; DE) was dissolved in 2.5 ml tap water to a final concentration of 0.5 ng/ μ L. Medroxyprogesterone acetate (Upjohn, Kalamazoo, MI) was dissolved in 2.5 ml tap water to a final concentration of 12 mg/ml. The rats received oral TAM (0.5ng/kg) or TAM-MPA (0.3 mg/kg) solution by a micropipet daily.

Experimental Protocol

The immature female rats were randomly divided into 2 groups; then they were administered TAM or TAM-MPA for 30 days according to the following protocol:

Group 1 (TAM, n=8), oral TAM (0.5 ng/kg) treatment was commenced daily.

Group 2 (TAM-MPA, n=8), oral TAM (0.5 ng/kg) and oral medroxyprogesterone acetate (0.3 mg/kg) treatment was commenced daily.

Following 30th day of treatment, all animals were sacrificed by over dose penthotal (Nembutal Sodium, Abbott) injection intraperitoneally 3 hours following the labelled TAM administration. Blood samples were




Figure 1. Mean tissue percentage uptake of TAM both in TAM and TAM+MPA treated rats.

obtained by cardiac puncture immediately after the sacrifice of the rats. The brain, hypophysis, lung, spleen, liver, right and left kidneys, right and left adrenals, right and left ovaries, heart, thymus and bicornuate uteri were collected from each animal by laparotomy and craniotomy.

Tamoxifen Analysis

Radiopharmaceutical: ^{99m}Tc-Tamoxifen citrate was prepared according to the following procedure: 10 mg tamoxifen citrate tablet was dissolved in 2 mL distilled water in a glass vial. (Nolvadex® Zeneca Co., England.) Nolvadex® (tamoxifen citrate) Tablets, a nonsteroidal antiestrogen, are for oral administration and contain 15.2 mg of tamoxifen citrate, (equivalent to 10 mg tamoxifen). In addition, each tablet contains as inactive ingredients: carboxymethylcellulose calcium, magnesium stearate, mannitol and strach.) The pH was adjusted to 5 with 0.5 NaOH. 0.2 mL SnCl₂. 2H₂O aq. solution (1 mg/mL) was added and mixed well. The mixture was passed through a 0.22 µm Millipore membrane filter into a sterile vial. 2 mL generator (Amersham International, Amersham, U.K.) eluate containing 370-555 MBq of ^{99m}Tc- pertechnetate was added and incubated at room temperature (R.T.) for 10 min. The labeling efficiency was determined by impregnated thin layer chromatography, using ready plates of TLC-SG (Gelman instrument Co.,

Ann Arbor, Mich., U.S.A.) 15 min after ^{99m}Tc-Tamoxifen citrate preparation. The sheets were put into 1 X 10 cm strips. Ten µL samples were applied at a point 1 cm from one end. The strips were developed in acetone or physiological saline. The solvents were allowed to reach 8 cm from the origin. The strips were cut into halves and the radioactivity in each segment was determined in a γ well-type counter (Model: DPC., Los Angeles, USA). Pertechnetate moved with the solvent front and hydrolyzedreduced (H-R) ^{99m}Tc remained at the point of application in both solvents. ^{99m}Tc-Tamoxifen citrate remained at the origin in acetone, but moved with the solvent front in saline. The labeling efficiency was determined by subtracting the sum of the amounts that migrated in acetone and that which remained at the origin in saline from %96. The stability of ^{99m}Tc-Tamoxifen citrate was tested at 0.5, 1, 3, and 24 h after storage at R.T. using the same method. The organs were weighed and counted from 1/1000 dilution of the solution. The percentage uptake of each organ and % administered dose/tissue were recalculated.

Results

All tissue weights were similar in both group. The highest mean percentage of TAM uptake was observed in




Figure 2. TAM uptake in kidneys, adrenals, thymus, heart, spleen and lung.

the hypophysis in both TAM and TAM-MPA treated groups ($p < 0.05$) (Fig. 1, 2).

But the TAM uptake was 5-fold higher to the TAM-MPA group compared with the TAM treated group. The mean percentage of TAM uptake were 3907.70255 in the TAM-MPA and 738.70245 in the TAM treated group. TAM uptake was detected 2, 4, 2, 9, 2-fold higher in the liver, ovaries, lung, kidneys and uterus than that serum in the TAM treated group respectively. In contrast, TAM uptake was lower in the lung, liver and uterus than the serum, but the renal uptake was still 5-fold higher when compared with the serum in the TAM-MPA treated group. The highest levels were observed in the kidneys (331.065, TAM treated; 627.0121 TAM-MPA) and the ovaries (128.9015, TAM treated; 159.5044, TAM-MPA) respectively after the levels in the hypophysis in both groups. Mean percentage of TAM uptake was significantly high in heart, serum, liver and kidneys in TAM-MPA group compared with TAM treated group ($p < 0.05$). TAM concentration in the uterus was higher in TAM-MPA group, but this difference was not significant ($p > 0.05$). Brain TAM concentrations were lower in both groups

(609.016, TAM treated; 497.106, TAM-MPA. Tissue distribution of TAM in TAM treated and TAM-MPA groups were similar after long term oral TAM and TAM-MPA administration.

Discussion

TAM has been extensively used as a chemotherapeutic agent in the treatment of breast cancer patients (1, 2). Recently, TAM has been considered to be prescribed for the primary prevention of the breast cancer in high risk women (2, 3). The tumorostatic effect of TAM has been directly related to the tissue concentrations of the drug in rats (4). Estrogenic effects of TAM have also been reported to breast cancer patients (12-14). Since MPA is known to prevent the estrogen induced changes in the endometrium, TAM and MPA may be used together in breast cancer patients. On the other hand, tumorostatic effect of TAM is not similar in different tissues (15). The results of these numerous report have been suggested the differences in the tissue distribution of TAM (6, 7, 8, 9).

The concentrations of TAM was detected 2-9-Fold higher in some organs, such as the liver, ovaries, lung and kidneys, than the serum levels. Similiar results have been reported following long term TAM administration both in human and animals (7, 8). Tissue accumulation of TAM may be related to the presence of the antiestrogenic-binding-sites (AEBS) in the tissue. Liver has been reported to have high levels of AERS (15). In the present study, TAM uptake was found to be high in the liver, furthermore, TAM uptake was high in TAM-MPA group compared with TAM treated group. Although the factors which are associated with AEBS changes in the liver are not clear yet, the higher level of TAM uptake may be the result of MPA treatment in combination with TAM.

In addition large amount of TAM was detected in the lung in both groups; this retention may be due to the interaction between the phospholipids and the TAM (16).

High levels of TAM was recovered from the kidneys and the TAM level was higher in TAM-DPA group than in the TAM treated group. The highest TAM uptake was observed in the hypophysis in the both groups, in contrast the brain has a minimal TAM concentrations. The low TAM concentrations in the brain has been reported in a previous study (6). These results have suggested that TAM crossed the blood-brain barrier. In human, equal amount of TAM and its metabolites were found in both normal brain tissue and the cerebral metastasis (17). TAM uptake was not affected from MPA treatment in the ovaries and the uteri.

As a conclusion, MPA treatment can alter the tissue distribution of TAM and the reason of high concentrations of TAM in the kidneys and the hypophysis needs to be explained by further experiments.

References

1. Sismondi P, Biglia N, Volpi E, Giai M, Grandis T. Tamoxifen and the endometrium. The human endometrium. (Eds. Bulletti C, Gorpide E, Flamigni C) The New York Academy of Sciences New York, 1994, pp: 10-321.
2. Bush TL, Helzlsouer K Tamoxifen for the primary prevention of breast cancer: A review and critique of the concept and trial. *Epidemiologic Reviews* 15 (1): 233-43, 1993.
3. Jordan VC. Long term adjuvant tamoxifen therapy for breast cancer. *Breast Cancer Res Treat* 15 (3): 125-36, 1990.
4. Wolf DM, Jordan VC. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. *Gynecol Oncol* 45: 118-128, 1992.
5. Robertson DW, Kwiwienellenbogen JA, Long DJ, Rorke EA, Kwiwienellenbogen BS. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. *J. Steroid Biochem* 16: 1-13, 1982.
6. Fronson JM, Pearson S, Bramah S. The metabolism of tamoxifen. Part II: In Female patients. *Xenobiotica*, 711-714, 1973.
7. Milano G, Etienne MC, Frenay M, Khater R, Formento JL, Rence N, Francoual M, Berto M, Namer M. Optimised analysis of tamoxifen and its main metabolites in the plasma cytosol of mammary tumours. *Br. J. Cancer* 35: 509-512, 1987.
8. Gottardis MM, Riccetto ME, Satyaswaroop PG, Jordan VC. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen - stimulated human endometrial (En Ca 101) in athymic mice. *Cancer Res* 50 (11): 3189-92, 1990.
9. Isserow S, Rucinski B, Romero DF, Mann GN, Liu CC, Epstein S. The effect of medroxyprogesterone acetate on bone metabolism in the oophorectomized, tamoxifen treated rat. *Endo* 136 (2): 713-719, 1995.
10. Gusberg SB. Tamoxifen for breast cancer: Associated endometrial cancer. *Cancer* 65: 1463-1464, 1990.
11. Lahli L, Blanco G, Kauppila A. Endometrial changes in postmenopausal breast cancer patients receiving TAM. *Obstet & Gynecol* 79: 111-1116, 1992.
12. Dilts PV, Hopkins ME, Chang A, Cody RL. Rapid growth of leiomyoma in patients receiving tamoxifen. *Am J Obstet Gynecol* 166: 167-8, 1992.
13. Roth RR, Vinegar A. Action by the lungs on circulating xenobiotic agents with a case study of physiologically based pharmacokinetic modeling of bez(a)ylene disposition. *Pharmacol Ther* 48: 143-155, 1990.
14. Lien BA, Wester K, Lenning PE, Solheim E, Ueland PM. Distribution of tamoxifen and metabolites into brain tissue and brain metastasis in breast cancer patients. *Br J Cancer* 63: 641-645, 1991.